Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 5/20 | 0.56 |
| ▸ | GABRD | O14764 | 5/20 | 0.56 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.56 |
| ▸ | GABRB1 | P18505 | 5/20 | 0.56 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.56 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.56 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.56 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.56 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.56 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.56 |
| ▸ | GABRA4 | P48169 | 5/20 | 0.56 |
| ▸ | GABRE | P78334 | 5/20 | 0.56 |
| ▸ | GABRA6 | Q16445 | 5/20 | 0.56 |
| ▸ | GABRG1 | Q8N1C3 | 5/20 | 0.56 |
| ▸ | GABRG3 | Q99928 | 5/20 | 0.56 |
| ▸ | GABRQ | Q9UN88 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15059144 | 0.84 | GABRP (0.61) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL29411268 | 0.79 | ALDH1A1 (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1300053 | 0.79 | ALDH1A1 (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2355355 | 0.78 | GAA (0.53) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL31472304 | 0.78 | GAA (0.53) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL19857495 | 0.78 | ASPH (0.60) | ALDH1A1TP53KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL6297457 | 0.78 | GABRP (0.58) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL5357531 | 0.78 | GABRP (0.58) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL14023609 | 0.76 | SORT1 (0.45) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2716579 | 0.76 | KDM4E (0.63) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106478497-B | Arylamine derivatives as TTX-S blockers | 拉夸里亚创药株式会社 | 2020-05-08 | — | — | CN | disclosed |
| CN-107406378-A | Sulfurized alkyl compounds and pyridine trans sulfonamide compounds for HBV treatment | 诺维拉治疗公司 | 2017-11-28 | — | — | CN | disclosed |
| CN-106478497-A | Aryl amine derivatives as TTX S blocker | 拉夸里亚创药株式会社 | 2017-03-08 | — | — | CN | disclosed |
| EP-2630122-B1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2016-11-30 | — | — | EP | disclosed |
| CN-103249721-B | Arylamine Derivatives as TTX-S Blockers | 拉夸里亚创药株式会社 | 2016-10-12 | — | — | CN | disclosed |
| US-9302991-B2 | Arylamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2016-04-05 | — | — | US | disclosed |
| CN-102317263-B | Halogen substituted compounds as pesticides | BAYER IP GMBH | 2015-04-22 | — | — | CN | disclosed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| EP-2630122-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc (JP) | 2013-08-28 | — | — | EP | disclosed |
| CN-103249721-A | Arylamine Derivatives as TTX-S Blockers | RAQUALIA PHARMA INC | 2013-08-14 | — | — | CN | disclosed |
| WO-2012053186-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | WO | disclosed |
| US-20090156575-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | US | disclosed |
| CN-101305005-A | Novel diazaspiroalkanes and their use for treatment of CCR8 mediated diseases | ASTRAZENECA AB (SE) | 2008-11-12 | — | — | CN | disclosed |
| EP-1926730-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | AstraZeneca AB (SE) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007030061-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2007-03-15 | — | — | WO | disclosed |
| EP-0100899-B1 | BENZISOSELENAZOLONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | A. Nattermann & Cie. GmbH (DE) | 1988-06-15 | — | — | EP | disclosed |
| US-4550168-A | Benzisoselenazolones and a process for the treatment of inflammatory diseases | A. NATTERMANN & CIE GMBH (DE) | 1985-10-29 | — | — | US | disclosed |
| EP-0100899-A2 | Benzisoselenazolones, process for their preparation and pharmaceutical compositions containing them | A. Nattermann & Cie. GmbH (DE) | 1984-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN2B, SCN1B, SCN2A | GABRP 342/4885GABRD 285/4885GABRA1 197/4885 |
| US-20090156575-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | CCR8, CCR1, CCR10 | GABRP 1172/4885GABRD 1270/4885GABRA1 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.